Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.31 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.30 |
| ▸ | CDK2 | P24941 | 2/20 | 0.30 |
| ▸ | TTK | P33981 | 2/20 | 0.30 |
| ▸ | AURKA | O14965 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2960852 | 0.90 | BRAF (0.37) | SYKCNR1CCNA2CDK2TTK | |
| Trifluoroacetic Acid SCHEMBL2933159 | 0.83 | MAPT (0.38) | CNR1CCNA2CDK2 | |
| SCHEMBL2931629 | 0.82 | MAPT (0.40) | CNR1CCNA2CDK2 | |
| SCHEMBL2931067 | 0.81 | BRAF (0.39) | CCNA2CDK2TTKAURKA | |
| SCHEMBL2928690 | 0.76 | AURKA (0.47) | SYKALOX15CCNA2CDK2TTK | |
| SCHEMBL2930097 | 0.76 | BRAF (0.37) | — | |
| Trifluoroacetic Acid SCHEMBL2960848 | 0.74 | TMEM97 (0.40) | CCNA2CDK2 | |
| SCHEMBL2935070 | 0.73 | BRAF (0.34) | SYK | |
| SCHEMBL2930653 | 0.73 | TMEM97 (0.43) | CCNA2CDK2TTK | |
| SCHEMBL2928646 | 0.73 | BRAF (0.37) | SYKCCNA2CDK2TTKAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2044051-B1 | PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS | BIOVITRUM AB PUBL (SE) | 2010-01-27 | — | — | EP | disclosed |
| US-20080039450-A1 | Compounds | BIOVITRUM AB (PUBL.) (SE) | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039450-A1 | Compounds | NEK2, CSNK2A3, CSNK2A1 | SYK 1798/4885CNR1 1076/4885ALOX15 4048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.